Log In
Print
BCIQ
Print
Print this Print this
 

Extended Release Carbinoxamine Oral Suspension, Karbinal ER carbinoxamine maleate

  Manage Alerts
Collapse Summary General Information
Company Tris Pharma Inc.
DescriptionOral antihistamine is formulated with Tris' OralXR+ technology
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationAllergy
Indication DetailsTreat allergies in children >=2 years of age
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today